Blood test could slash antibiotic use in preterm infants
NCT ID NCT06100614
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 39 times
Summary
This study tests whether a rapid blood test called presepsin can safely reduce unnecessary antibiotic use in very preterm babies (born before 32 weeks). Currently, over 85% of these infants get antibiotics right after birth due to infection risk, but only about 1 in 70 actually has an infection. The trial will compare standard care to care guided by the presepsin test, aiming to cut antibiotic use by at least 30% without missing any real infections. Around 900 babies will take part across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-ONSET NEONATAL SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Presepsin diagnostic test
What this could lead to
If successful, this test could help doctors avoid giving antibiotics to many preterm babies who don't need them, reducing side effects.
What could go wrong
The test might not be accurate enough to safely rule out infection, potentially missing some cases of sepsis. Results are from a single trial and need confirmation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.